 |
|
|
| |
Centering Community Leadership with PURPOSE: Inclusion of Adolescents, Cisgender Women, and Pregnant and Lactating Individuals in a Phase 3 Clinical Trial Evaluating Lenacapavir and Emtricitabine/Tenofovir Alafenamide for PrEP
|
| |
| |
AIDS 2024 July 20-26 Munich
|
| |
|
|
|
|
|
